



VistaGen® Therapeutics

COMPANY OVERVIEW

<https://ir.vistagen.com/tear-sheet>

RECENT NEWS

[VistaGen Therapeutics Reports Fiscal 2019 First Quarter Financial Results](#)

Aug 14 2018, 4:49 PM EDT

[VistaGen Therapeutics and Baylor College of Medicine Collaborate on First-Step Study to Test VistaGen's AV-101 for Potential Anti-Suicidal Effects in Veterans](#)

Aug 13 2018, 8:30 AM EDT

[VistaGen Therapeutics Reports Fiscal Year 2018 Financial Results and Provides Year-to-Date Highlights](#)

Jun 26 2018, 5:12 PM EDT

STOCK OVERVIEW

Symbol	VTGN
Exchange	Nasdaq
Market Cap	33.82m
Last Price	\$1.31
52-Week Range	\$0.69 - \$2.65

INVESTOR RELATIONS

VistaGen Therapeutics, Inc.
 Mark A. McPartland
 Vice President, Corporate
 Development
 (650) 577-3606
markmcp@vistagen.com
 KCSA Strategic Communications
 Valter Pinto / Allison Soss
 (212) 896-1254 / (212) 896-1267
VistaGen@KCSA.com

MANAGEMENT TEAM

Shawn K. Singh
 Chief Executive Officer and Director

H. Ralph Snodgrass, Ph.D.
 Founder, President, Chief Scientific Officer
 and Director

Mark A. Smith, M.D., Ph.D.
 Chief Medical Officer

Jerrold D. Dotson, CPA
 Vice President, Chief Financial Officer and
 Secretary

Mark A. McPartland
 Vice President of Corporate Development

VISTAGEN THERAPEUTICS, INC.

343 Allerton Avenue
 South San Francisco, CA 94080

DISCLAIMER

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.